02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
02:33 , Dec 8, 2018 |  BioCentury  |  Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
17:51 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

New BCMA-targeted therapies could help sicker patients

Oral abstracts at this year’s American Society of Hematology meeting describing next generation anti-BCMA CARs from Poseida Therapeutics Inc. and Fred Hutchinson Cancer Research Center and a bispecific antibody from Amgen Inc. (NASDAQ:AMGN) hint that...
23:00 , Dec 4, 2018 |  BC Extra  |  Clinical News

New BCMA-targeted therapies could help sicker patients

Oral abstracts at this year’s American Society of Hematology meeting describing next generation anti-BCMA CARs from Poseida Therapeutics Inc. and Fred Hutchinson Cancer Research Center and a bispecific antibody from Amgen Inc. (NASDAQ:AMGN) hint that...
19:51 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma. On the...
22:23 , Nov 1, 2018 |  BC Extra  |  Clinical News

BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma. On the...
23:56 , Jul 26, 2018 |  BC Extra  |  Company News

Reese succeeding Harper as Amgen EVP of R&D

Amgen Inc. (NASDAQ:AMGN) said EVP of R&D Sean Harper will retire and be succeeded by SVP of Translational Sciences and Oncology David Reese. The company also reported 2Q18 earnings on Thursday after market hours that...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Boehringer Ingelheim, Amgen deal

Boehringer granted Amgen worldwide rights to develop and commercialize BI 836909 ( AMG 420 ), a compound in Phase I testing to treat relapsed and/or refractory multiple myeloma (MM). BI 836909 is a bispecific T...
07:00 , Sep 1, 2016 |  BC Extra  |  Company News

Amgen licenses Boehringer MM candidate

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted Amgen Inc. (NASDAQ:AMGN) global rights to develop and commercialize multiple myeloma candidate BI 836909 (AMG 420). Financial details were not disclosed. BI 836909, a bispecific T cell engager (BiTE)...